MKKGY News and Press, Merck KGaA ADR From 03/02/23

The following slide deck was published by MERCK Kommanditgesellschaft auf Aktien in conjunction with their 2022 Q4 earnings call. For further details see: MERCK Kommanditgesellschaft auf Aktien 2022 Q4 - Results - Earnings Call Presentation

MERCK Kommanditgesellschaft auf Aktien (MKGAF) Q4 2022 Results Earnings Conference Call March 2, 2023, 08:00 AM ET Company Participants Constantin Fest - Head of Investor Relations Belén Garijo - Chair of the Executive Board and Chief Executive Officer Marcus Kuhn...

Summary Gossamer's TORREY showed stat sig PVR improvement, but the 6MWD was under what investors were hoping for; this led to a +70% decline in share price. Seralutnib is entering phase 3 with an adapted design (with more severe patients); although the success is less clear, any positiv...

Summary FSTX seems undervalued, even at the $7.12 takeover bid. The CFIUS is delaying the closure of the deal, citing review needed to allay US national security concerns. If the deal closes, the stock should rise 30%; if it fails, FSTX still has very valuable assets. The only r...

Summary Mersana has excellent ADC science. A number of big pharma have bought into the science. However, currently available data leaves a lot to be desired. Mersana ( MRSN ) is a small-cap developer of antibody drug conjugate molecules targeting oncology indications. ...

Summary The Top Six Healthcare Products and Service companies are some of the most popular investments in the market. However, they offer varying financial profiles. To understand where opportunity may lie, I ranked the group according to various financial metrics. Read on to se...

Summary FDA and EU approved, the joint therapy Enhertu is set to become a blockbuster. The therapy targets HER-2 cancers and is already expanding indications beyond breast cancer. With this successful antibody-drug conjugate, the entire sub-industry is now seeing renewed momentum he...

Summary Big pharma performed well in 2022, but the time to trim is drawing close. As a more diversified investment, I believe former parent company of Merck & Co, Merck KGaA offers a better long-term investment. With diversification and strong fundamentals, Merck KGaA is a far b...

Merck KGaA ( OTCPK:MKGAF ) ( OTCPK:MKKGY ) said its unit MilliporeSigma's Life Science business sector is investing more than $286M in its biosafety testing capacity at the site in Rockville, Maryland. The investment will boosts the company's ability to conduct bi...

MERCK Kommanditgesellschaft auf Aktien (MKGAF) Q3 2022 Earnings Conference Call November 10, 2022 08:00 AM ET Company Participants Constantin Fest - Head, IR Belen Garijo - Group, CEO Marcus Kuhnert - Group CFO Matthias Heinzel - CEO, Life Science Kai Bec...